SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals zooms on 'Zero' observations from USFDA for Hyderabad laboratory

26 Jun 2025 Evaluate

SMS Pharmaceuticals is currently trading at Rs. 250.05, up by 11.00 points or 4.60% from its previous closing of Rs. 239.05 on the BSE.

The scrip opened at Rs. 254.85 and has touched a high and low of Rs. 258.35 and Rs. 249.10 respectively. So far 17972 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 398.00 on 23-Sep-2024 and a 52 week low of Rs. 175.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 258.35 and Rs. 229.55 respectively. The current market cap of the company is Rs. 2220.73 crore.

The promoters holding in the company stood at 66.26%, while Institutions and Non-Institutions held 2.51% and 31.22% respectively.

United States Food and Drug Administration (USFDA) has concluded inspection at SMS Pharmaceuticals’ Central Laboratory Analytical Services, located at Hyderabad, Telangana. The inspection, conducted from June 23, 2025 to June 25, 2025, concluded with zero Form 483 observations. 

The Company is committed to meeting the highest quality standards and is further committed to full compliance with CGMP & GLP regulations at all its manufacturing & Analytical facilities. The Central Laboratory Analytical Services is company’s independent testing laboratory, and this was the second successful USFDA inspection for the facility.

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers.

SMS Pharmaceuticals Share Price

396.55 -19.20 (-4.62%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×